The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the

E Sabattini1, K Bisgaard, S Ascani

  • 1Haemolymphopathology, Unit, University of Bologna, Italy.

Insights

The EnVision++ immunohistochemical detection system offers higher antibody dilutions and reproducible results, reducing costs and assay time. It is an easy-to-use, two-step procedure beneficial for various sample types.

Area of Science:

  • Immunohistochemistry
  • Biotechnology
  • Pathology

Background:

  • Immunohistochemistry (IHC) is crucial for diagnosing diseases and understanding biological processes.
  • Existing detection systems have limitations in sensitivity, reproducibility, and cost-effectiveness.
  • The development of novel IHC detection systems is essential for advancing diagnostic capabilities.

Purpose of the Study:

  • To evaluate the performance of the newly developed EnVision++ immunohistochemical detection system.
  • To compare EnVision++ with established IHC detection methods, including APAAP, CSA, LSAB, SABC, and ChemMate.
  • To assess the system's utility across a range of sample types and antibody specificities.

Main Methods:

  • A comprehensive series of normal and pathological tissue samples were utilized.
  • Fifty-three monoclonal antibodies were tested using a chessboard titration assay.
  • EnVision++ performance was compared against APAAP, CSA, LSAB, SABC, and ChemMate, both manually and with the TechMate 500 immunostainer.

Main Results:

  • EnVision++ enabled two- to fivefold higher antibody dilutions compared to APAAP, LSAB, SABC, and ChemMate, maintaining staining intensity and positive cell percentage.
  • The system demonstrated superior reproducibility with variously fixed or overfixed samples, particularly for critical antibodies like anti-CD5.
  • The tyramide-based enhancement CSA method matched EnVision++ dilutions, and in one case (anti-cyclin D1), was considered the gold standard.

Conclusions:

  • EnVision++ is an user-friendly IHC detection system that mitigates issues with endogenous biotin.
  • It reduces per-test costs by allowing higher primary antibody dilutions.
  • The two-step procedure of EnVision++ shortens assay time and decreases laboratory workload.
Abstract